CortheraBio

The company’s third pipeline product, CTB-02, is a cocktail therapy with novel combinations discovered through Cothera’s i-CR® Platform. CTB-02 targets colon cancer and non-small cell lung cancer with pan-KRAS mutations. There are currently no approved targeted therapies for KRAS-mutant colorectal cancer, resulting in huge clinical unmet needs. In CDX and PDX animal experiments, CBT-02 demonstrated powerful inhibitory effect not only on KRAS G12C-mutated colorectal cancer, but also on cancers with other KRAS mutations.

The CTB-02 program is currently in Phase 1b clinical development.

CortheraBio
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.